Investors Urged to Participate in Class Action Against Capricor Therapeutics Over Alleged Securities Fraud

Overview of the Class Action Lawsuit Against Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is currently facing a class action lawsuit spearheaded by the Schall Law Firm, a well-known litigation firm specializing in shareholder rights. The case, which investigates purported violations of sections 10(b) and 20(a) of the Securities Exchange Act of 1934, has come to light due to alleged misleading statements made by the company during the class period, which spans from October 9, 2024, to July 10, 2025.

Background Information

Investors who acquired securities of Capricor during this timeframe are invited to participate in the lawsuit. The suit centers around claims that the company provided false assurances regarding its drug candidate, deramiocel, particularly in the context of its progress toward obtaining FDA approval. During the class period, Capricor allegedly indicated a favorable direction marked by a mid-cycle review without major deficiencies and an upcoming advisory committee meeting. However, it is important to note that these optimistic projections were allegedly made while the company concealed critical adverse data from the Phase 2 HOPE-2 trial.

Legal Implications

The Schall Law Firm has emphasized the potential for financial recovery for investors who have suffered losses due to these alleged misrepresentations. According to the firm, if the claims are substantiated, investors may be able to recover their losses occurring from the time when the company publicly communicated misleading information until the truth about the drug's trial outcomes was revealed. This event likely led to a significant decline in stock value and thus incurred damages to the investors' portfolios.

How to Get Involved

Interested investors are urged to reach out to the Schall Law Firm before the deadline of September 15, 2025, to ensure they are effectively represented. It is critical to understand that without taking appropriate legal action and joining the lawsuit, investors may remain unrepresented and at risk of missing out on a potential recovery. For further information, investors can contact Brian Schall directly at the Schall Law Firm's Los Angeles office through the provided contact details.

Current Status of the Lawsuit

As of the latest updates, the class for this lawsuit has not yet been certified. This detail carries importance for potential participants, as certification is a necessary legal hurdle that must be overcome to proceed with the claims. Until such certification occurs, individuals who remain passive will find themselves categorized as absent class members, with no legal representation and potentially no chance for recovery for their losses.

The Path Ahead

Schall Law Firm, widely recognized for its extensive work in securities class action litigation, invests in protecting investors' rights and seeking justice for those who have been misled. As the case develops, the firm will continue to provide updates regarding the legal proceedings, enabling participants to stay informed about their case's progression.

This lawsuit embodies a crucial opportunity for investors seeking to hold Capricor accountable for any deceitful behavior that may have impacted shareholder investments. It serves as a reminder of the importance of transparency and accountability in the biotech sector, where the stakes are often incredibly high, and the impact on investors can be profound.

In conclusion, if you are an investor in Capricor Therapeutics who believes they have suffered losses based on misleading information released during the class period, it is advisable to consider joining this lawsuit. By taking action, you can stand up for your rights as a shareholder and potentially recover your losses as the legal process unfolds.

For any inquiries or to discuss your rights, feel free to contact the Schall Law Firm directly through their official website or phone line. Remember, your participation is pivotal in seeking justice and compensation in light of these serious allegations.